2 KEYWORDS: Nanostructures; Lipids; Microfluidics; Interfaces; Drug delivery ABSTRACT: The functionalized lipid shell of hybrid nanoparticles plays an important role for improving their biocompatibility and in vivo stability. Yet few efforts have been made to critically examine the shell structure of nanoparticles, and its effect on cell-particle interaction.
Here we develop a microfluidic chip allowing for the synthesis of structurally well-defined lipidpolymer nanoparticles of the same sizes, but covered with either lipid-monolayer-shell (MPs, monolayer nanoparticles) or lipid-bilayer-shell (BPs, bilayer nanoparticles). Atomic force microscope (AFM) and atomistic simulations reveal that MPs have a lower flexibility than BPs, resulting in a more efficient cellular uptake and thus anti-cancer effect than BPs do. This flexibility-regulated cell-particle interaction may have important implications for designing drug nanocarriers.
Lipid-polymer hybrid nanoparticles (LNPs) loaded with drugs are emerging as sophisticated therapeutic agents. [1] [2] [3] [4] These NPs present high drug encapsulation efficiency, prolonged circulation half-life, high stability, and efficient cellular uptake. [5] [6] [7] To fabricate these LNPs, two categories of approaches have been developed: 1) The two-step method by separately preparing the polymeric nanoparticles and aqueous lipid films/liposomes, followed by constructing coreshell nanoparticles through extrusion, sonication, or electrostatic interaction; 8, 9 2) the one-step method combining nanoprecipitation of polymeric nanoparticles and simultaneous self-assembly of the lipid shell. 10, 11 It is worth noting that the different fabrication strategies may result in the formation of multilamellar or unilamellar lipid shell covering the polymeric core. 12, 13 The 3 different lipid structures may affect the physicochemical properties of LNPs. Yet few efforts have been made to critically examine the shell structure of nanoparticles, and its effect on cellparticle interface or the efficacy in disease treatment. This might be due, to a large extent, to the lack of adequate techniques to precisely control the lipid shell structures of LNPs.
In our previous study, 5 we synthesized two kinds of core-shell hybrid NPs with different rigidity by modulating the amount of interfacial water between polymeric core and lipid shell.
The correlation between the rigidity of NPs and their cellular uptake efficiency has been investigated, with rigid NPs being easier to be internalized by cells than soft ones. In addition to the interfacial water inside NPs that regulates the cell-particle interface, we postulate that the distinct lipid shell structure of hybrid NPs may also mediate the particle flexibility and its efficiency in cancer therapy. To investigate the role of lipid shell, the accurate assembly of varying lipid layers onto the polymeric cores is a prerequisite, which might be difficult to achieve by traditional approaches.
In this work, via a specifically designed microfluidic chip, we realize the synthesis of 4
RESULTS AND DISCUSSION

Fabrication of MPs and BPs
To fabricate LNPs with controlled lipid shell structures, we adopt a two-stage microfluidic chip. Figure 1 ). We note that such assembly is assisted with the spiral structure at the second stage of microfludics. 16 From the synthesis process we may deduce that in mode A the LNPs are covered by lipid-monolayer-shell (named as MPs, monolayer nanoparticles) while in mode B, LNPs are coated by lipid-bilayer-shell (named as BPs, bilayer nanoparticles, Figure 1 ). To explore the practicality of process, we characterize the LNPs with cryo-transmission electron microscope (Cryo-TEM), and observe a structural difference of outer lipid shells between MPs and BPs (Figures 1 and S1 ). The electron density cross the lipid layer structure shows that BP has a bilayer shell structure with the thickness of ~ 4 nm (Figures 1 and S1 ). We should note that due to the existence of interfacial water between PLGA core and lipid bilayer shell in BPs, 5 the interaction between PLGA and lipid bilayer is 5 relatively weak, so that we can observe a corona of lipid bilayer with a characteristic thickness of ～ 4 nm by Cryo-TEM. 17 For MPs covered with lipid monolayer, the hydrophobic tails of lipids are embedded into the PLGA surface. In this case, the lipid monolayer cannot be distinguished from TEM due to the tight contact between the PLGA core and the hydrophobic tail of lipid ( Figure 1 ). 
Characterization of MPs and BPs by DLS
We next evaluate the amount of lipids for complete coverage on the PLGA core of MPs and BPs by dynamic light scattering (DLS). Previous studies and our experiments indicate that only LNPs completely covered by lipids are stable in both water and PBS while PLGA nanoparticles or liposomes may experience aggregation in PBS, resulting in an increase in size ( Figure S2 , Materials and Methods). 18 By varying the PLGA/lipid (w/w) ratio from 8 to 1, we observe a similar size distribution of MPs (mode A) in both water and PBS at a ratio of 4. Interestingly, to generate stable lipid-covered BPs in mold B, the PLGA/lipid ratio should be decreased to 2 ( Figure S3 ). This result suggests that BPs require twice the amount of lipids compared to MPs for completely covering the PLGA cores, to form the lipid bilayer shell. We should note that to prepare pure PLGA nanoparticles via a microfluidics-based nanoprecipitation, we introduce 
Characterization of MPs and BPs by fluorescence quenching
We further adopt the fluorescence quenching method to characterize the lipid monolayer-or bilayer-shell. 19 We synthesize the NBD-DSPE Figure S5 ). Both MPs and BPs show the ball shape, the diameter of which is similar to
Cryo-TEM observation. However, BPs have a higher deformation and energy dissipation than MPs (Figures 2B-C, and 2E-F). 21 The large particle deformation may be attributed to the high flexibility of BPs containing lipid bilayer shell, since previous study indicates that the selfassembled lipid bilayer structure could display fluidic and elastic properties. 24 In addition to particle flexibility, we also discuss the mechanical variation of MPs and BPs from an energetic aspect. The energy dissipation refers to the energy which is dissipated from AFM tip into the NPs during every cycle as the AFM tip is approached and withdrawn from the NPs. The quantity of dissipated energy during one cycle equals to the net area between the approach force-distance curve (FDC, solid line) and withdrawal FDC (dash line, Figure 2G ). Measuring tens of NPs, the energy dissipation of MPs and BPs is summarized, showing that the energy dissipated in MPs is much smaller than the value recorded on BPs ( Figure 2H ). In this case, we propose that the huge difference of dissipated energy in MPs and BPs is related to the varying lipid structure and flexibility 25 : more flexible BPs result in a larger contact area at the AFM tip-particle interface than MPs, thus leading to a higher dissipation energy caused by the frictional force between the 
MD simulations of flexibility-regulated interaction
To verify the different energy dissipation of MPs and BPs in the AFM experiments, we also perform indentation by molecular dynamics (MD) simulations. [26] [27] [28] The simulation system Moreover, the net area between the approach and withdrawal FDC is remarkably higher for BPs structure than that of MPs. We note that in the MD simulations we have selected a relatively small model system so that the dissipation energies do not agree with the experimental ones in their exact numbers. However through the simulations, the mechanism of structure difference between MPs and NPs induced different dissipation energy, and the process of particle deformation during the interaction are clarified. Table S2 , and Materials and Methods). We speculate that
BPs of high flexibility dissipate a larger energy at the LNPs-cell interface, and are more difficult to be internalized by cancer cells than MPs. Our previous investigation also proves that MPs show an enhanced cellular uptake compared with BPs, albeit via the same internalization pathway. 5 We should note that stiffer NPs have higher cellular uptake efficiency than softer ones; 13 however, the similar structured core-shell microparticles with diameter of several micron show the opposite biological effect where softer microparticles are more efficiently. 32 This might be due to the distinct pathways of cellular uptake of particles with different sizes. In our case the NPs are internalized via endocytosis, yet the passive diffusion of microparticles. The detailed mechanisms for such contrasting results between particles at different size regimes warrant further investigation. 
Flexibility-regulated anti-cancer efficacy and in vivo imaging
We also perform in vivo investigation into the effects of drug-loaded 
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In vivo imaging shows that MPs tend to accumulate in tumor sites more rapidly than BPs ( Figure   S9 ). The comparison of ex vivo tumors after 16 h treatment indicates a higher uptake amount of MPs than BPs ( Figure 4E ). 
Biocompatibility of MPs and BPs
To examine whether this mono-/bilayer lipid coating will affect the cell membrane, we first Figure 5E ), indicating that our lipid-coated core-shell NPs have negligible liver toxicity. We further evaluate the toxicity of drug-loaded MPs or BPs to major organs including heart, liver, Figure   5F ). From the above two experiments, we can conclude that both MPs and BPs show good in vivo biocompatibility. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Design and fabrication of the microfluidic chip. The microfluidic chip consists of two stages:
(1) the first stage have three inlets and a straight synthesis microchannel; (2) the second stage have one centered inlet and a spiral mixing channel ( Figure S1 ). The three inlet channels at the first stage are 100 µm in width, and 50 µm in depth. The main horizontal channel at the first stage is 300 µm in width, and 50 µm in depth. The inlet channel at the second stage is 300 µm in width, and 50 µm in depth. The double spiral channel at the second channel is 300 µm in width, and 50 µm in depth, which first rotates in the counterclockwise direction for 3 loops, changes the direction through an S-shaped junction, then rotates in the clockwise direction.
The microfluidic device was fabricated using standard soft lithography. SU-8 2050 photoresist (MicroChem Corp) was first spin-coated on a 4 inch silicon wafer at 500 rpm for 10 sec followed by 3000 rpm for 30 sec to obtain the desired thickness (50 µm). The coated wafer 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Nanoprecipitation of hybrid nanoparticles. 100 mg PLGA was dissolved in 6.5 mL DMF and 3.5 mL TFE to prepare 1 % PLGA solution (10 mg/mL). Lipid solution was composed of DPPC 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 20 PBS while PLGA NPs or liposomes by themselves may experience aggregation in PBS, resulting in an increase in size shift ( Figure S2 ). By varying the PLGA/lipid ratio from 8 to 1, we observe a homogeneous size distribution of MPs (mode A) in both water and PBS at a ratio of 4 ( Figure   S3 ). A higher or lower ratio leads to a small shift of peak position in PBS versus water due to the aggregation of excess PLGA NPs or liposomes in PBS. In comparison, we need to decrease the PLGA/lipid ratio to 2 to prevent aggregation of BPs (mode B) in PBS ( Figure S3 ). This NBD quenching method is based on the fact that that sodium dithionite reacts more rapidly with NBD in the outer lipid layer than that in the inner lipid layer. By controlling the reaction time and amount of sodium dithionite, the reaction could be limited to NBD in the outer lipid layer. We added the sodium dithionite dropwise (1.4 µL per drop, 200 mM, pH 10) to 400 µL nanoparticle suspensions, and the fluorescence spectra were continuously detected until the reduction of fluorescence was stable ( Figure S4 ). The fluorescence in MPs was quenched to a constant value after 3 drops due the complete reaction of NBD at the outer lipid layer, while for the liposomes and BPs, the constant fluorescence value was obtained after 6 drops. The reduction of fluorescent intensity at 530 nm with increasing amount of sodium dithionite was compared to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table S1 .
We use a velocity-Verlet algorithm to perform time integration, and Langevin thermostat Table   S2 .
In vivo tumor growth inhibition study. mg/kg for CA4) to reduce the toxicity of the drug and the potential side-effects of treatment. We should note that the concentration of encapsulated drugs inside hybrid nanoparticles is the same as that of free drugs; however, the hybrid nanoparticles, especially monolayer coated nanoparticles (MPs), exhibit an efficient anti-cancer therapy due to the enhanced cellular uptake.
For drug loaded PLGA NPs, there are three key factors to ensure their therapeutic effects.
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In vivo imaging. In vivo
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